Skip to content
Kalpvruksh Markets
Offline Log in

EMCURENSEOffline

EMCURE PHARMA · INE168P01015 · Small Cap · #271
2,245.00+84.60 (+3.92%)last close · 05 Nov 2026
Prev close
2,160.40
Open
—
High
—
Low
—
Volume
—
Mkt cap (6-mo avg)
₹30,247 cr
52-week range · to 05 Nov 20261,318.92,245

Loading minute bars…

NSE 1-minute bars from our CandleApi gateway (history from 21 Jul 2026); longer timeframes are built from them. Prices not adjusted for corporate actions.

EMCURE is at its 52-week high, above its 200-day average, ahead of Healthcare by 13.5 pts over 3 months — a Small Cap company, #271 by market cap.NSE prices to 05 Nov 2026 · a description of the data, not advice

Overview

What the data says, line by line

A description, never a buy or sell word · tap a line for its detail

  • above its 20 / 50 / 200-day averages · at its 52-week high
  • ahead of its industry by 13.5 pts over 3 months · rank 1 of 44 in Healthcare · +17.1% vs Nifty 500
  • traded value 6.1× usual · delivery 47% vs 54% usual
  • FPI +0.1 pp · DII +0.0 pp · MF schemes in Sept 2026: 41 bought, 6 cut · promoter pledge 0.04% · quarter ended 2026-09-30
  • Jun 2026 quarter: profit +42% year on year · revenue +23%
  • ftse large_mid: close to add (2027-03)

How big is it?

six-month average market cap

Market capitalisation
₹30,247 cr
Rank
#271
Cap band
Small Cap
Nearest cut-off — Mid / Small
−11.53% from ₹34,190 cr
Clear of the cut-off

Our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page.

Did buyers take delivery?

latest session · 2026-11-05

vs its own normal
5.3×
median 54,175
Delivered
2,84,501
Of volume
50%

Price & trend

Returns

to 05 Nov 2026

PeriodStockvs Nifty 500vs its industry
1 week+20.4%+13.7 pts—
1 month+16.8%+11.6 pts+12.4 pts
3 months+14.6%+17.1 pts+13.5 pts
6 months+35.3%+34.7 pts+22.0 pts
1 year+67.8%+72.3 pts—

Industry: Healthcare (Nifty 500 classification) · rank 1 of 44 over 3 months. Points = the stock’s return minus the benchmark’s. Prices adjusted for splits and bonuses.

Averages & movement

vs 20-day average
+19.6%
above
vs 50-day average
+17.8%
above
vs 200-day average
+29.4%
above
ATR (14)
4.4%
typical daily range
Volatility
44%
1 month, annualised
Beta
0.58
vs Nifty 500, 1 year
Traded value
6.1×
vs usual
Delivery
47%
usual 54%
From the 52-week high
0.0%
place in range 100% (0 = at the low)

Ownership

Who owns the company

% of all shares, by quarter

GroupDec 25Mar 26Jun 26Sep 26
Promoters77.9%77.9%77.8%77.8%
FPI3.6%3.4% −0.24.9% +1.54.9% +0.1
Mutual funds4.8%4.9% +0.16.9% +1.97.0% +0.2
Other DII1.3%1.2% −0.11.6% +0.41.4% −0.1
Individuals6.5%6.5%6.5%6.3% −0.1
Others6.0%6.2% +0.22.4% −3.82.4%

From the company’s quarterly shareholding pattern. Changes in percentage points against the quarter before. No quarters are on record between Sep 2022 and Jun 2025.

Promoter pledge

Sep 26

Of promoters’ holding
0.04%
Of all shares
0.03%
Jun 25 0.04%Sep 25 0.04%Dec 25 0.04%Mar 26 0.04%Jun 26 0.04%Sep 26 0.04%

Holders

Sep 26

All shareholders
1,29,328
Individuals
1,23,846

Indian passive funds’ stake

2026-06-30

Of free float
0.49%
Of all shares
0.11%
Schemes
43
Days to unwind
0.8
at 100% of volume

2,04,688 shares held by Indian passive mutual-fund schemes. A floor, not the total — foreign ETFs, insurance and EPFO are not counted.

Which funds bought and sold

mutual funds · quarter ended 2026-06-30

Funds holding
72
43 index · 29 active
Bought more
36
Sold some
11
FundSharesChangeDid
Aditya Birla SL Small Cap Fund(G)Active+2,61,420+261.4%bought
HSBC Small Cap Fund-Reg(G)Active+2,09,580+31.0%bought
Kotak Healthcare Fund-Reg(G)Active+5,000+10.0%bought
DSP Healthcare Fund-Reg(G)Active−3,18,121−82.0%sold
Aditya Birla SL Bal Bhavishya Yojna-Reg(G)Active−32,296−29.4%sold
Nippon India Multi Cap Fund(G)Active−4,15,774−19.4%sold

Ranked by how much each fund changed its own position, not by size of trade. Every fund here still holds the company — one that sold out entirely leaves no record to find.

Mutual-fund schemes, month by month

fund houses’ own monthly portfolios

MonthSchemesBought newAddedCutSold outShares heldValue
Sep 266523951−0.5%₹1,691 cr
Aug 266443241−2.0%₹1,624 cr
Jul 2661326125−1.4%₹1,751 cr
Jun 2663626162+0.7%₹1,662 cr
May 2659122152+0.2%₹1,524 cr
Apr 266043066−1.2%₹1,507 cr

Each month against the one before, counting only the fund houses that reported both (45 houses in Sep 26); a split or bonus is divided out first. “Partial” = fewer than five houses reported yet.

Fund ownership is a quarterly disclosure and counts Indian passive schemes only.

Results

Results

Events & filings

Disclosures & deals

last six months · NSE filings

  • Board outcome
    Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
    03 Nov 2026
  • Credit rating
    Emcure Pharmaceuticals Limited has informed the Exchange about Credit Rating
    01 Sept 2026
  • Board outcome
    Emcure Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.
    06 Aug 2026
  • Scheme / acquisition
    Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
    13 Jul 2026
  • Scheme / acquisition
    Emcure Pharmaceuticals Limited has informed the Exchange about Acquisition
    03 Jul 2026
  • Takeover (SAST)
    Satish Mehta, Sunil Mehta, Samit Mehta and Namita Thapar has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
    23 Jun 2026
  • Bulk deal: SELL
    9,69,729 at ₹1,817 — BC INVESTMENTS IV LIMITED
    25 Jun 2026
  • Bulk deal: SELL
    9,69,730 at ₹1,817 — BC INVESTMENTS IV LIMITED
    25 Jun 2026
  • Block deal: BUY
    2,61,420 at ₹1,817 — ADITYA BIRLA SUN LIFE MUTUAL FUND
    25 Jun 2026
  • Block deal: BUY
    1,37,593 at ₹1,817 — ALPHA ALTERNATIVES EQUITY ABSOLUTE RETURN FUND
    25 Jun 2026

Latest shown; 11 in six months on all disclosures.

EMCURE: only ratings, pledges, insider and takeover disclosures, buybacks, schemes, board outcomes and deals are listed. All deals.

Corporate actions

full published history

0 selected
RecentDividend₹3.6Final04 Sept 202604 Sept 2026
EarlierDividend₹3Final14 Aug 202514 Aug 2025

2 shown. A falling price on an ex-date is not a loss: a dividend leaves the share as cash and a bonus multiplies the shares held.

Market capitalisation is our own six-month average, computed the way AMFI computes it; the published classification is on the market cap page. Fund ownership is a quarterly disclosure and counts Indian passive schemes only. Nothing here is advice, a recommendation, or a view on the company.